Welcome to our dedicated page for Ge Healthcare Technologies SEC filings (Ticker: GEHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GE HealthCare Technologies Inc. (GEHC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation with common stock listed on Nasdaq under the symbol GEHC, GE HealthCare submits periodic and current reports that offer detail on its financial condition, governance, and significant corporate events.
Among the key documents investors often review are Form 10-K annual reports and Form 10-Q quarterly reports, which contain information on the company’s operations across its Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses. In addition, Form 8-K current reports disclose material events. Recent 8-K filings have described items such as a three-year senior unsecured term loan credit facility, the issuance of senior notes due 2028 and 2035, the intended use of proceeds in connection with an announced acquisition of Intelerad Medical Systems, quarterly financial results, and changes to the board of directors.
Investors interested in GEHC can also use this page to track other filing types, such as registration statements and, when applicable, proxy materials related to governance matters. These documents help explain the company’s capital structure, including senior notes and credit facilities, and outline covenants, events of default, and other terms referenced in the filings.
Stock Titan enhances access to GE HealthCare’s filings by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries that highlight key points in lengthy documents. This can help users quickly understand the implications of new 10-K, 10-Q, and 8-K filings, as well as monitor developments related to financing arrangements, acquisitions, and other significant events disclosed by GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. Chief Technology Officer Taha Kass-Hout reported a routine tax-related share withholding. On February 1, 2026, 847 shares of common stock were withheld at $78.97 per share to cover tax obligations tied to vesting restricted stock units.
After this transaction, Kass-Hout beneficially owns 64,103 shares of GE HealthCare common stock in direct ownership. This filing reflects an administrative tax settlement rather than an open-market purchase or sale.
GE HealthCare Technologies Inc. Chief Accounting Officer George A. Newcomb reported a tax-related share withholding. On 02/01/2026, 108 shares of common stock at $78.97 per share were withheld to cover tax obligations tied to vesting restricted stock units.
After this transaction, Newcomb beneficially owned 7,597 shares directly and 12 shares indirectly through a family member.
GE HealthCare Technologies Inc. officer Roland Rott, CEO of Imaging, reported a routine tax-related share withholding. On February 1, 2026, 558 shares of common stock were withheld at $78.97 per share to cover tax obligations from vesting restricted stock units. After this transaction, Rott directly owned 28,564 shares of GE HealthCare common stock.
GE HealthCare Technologies Inc. GC & Corporate Secretary Frank R. Jimenez reported an automatic share withholding related to equity compensation. On February 1, 2026, 947 shares of common stock were withheld at $78.97 per share to cover tax obligations on vested restricted stock units. After this transaction, he directly beneficially owned 67,546 shares of GE HealthCare common stock.
GE HealthCare Technologies Inc.’s Chief Financial Officer, James Saccaro, reported a routine tax‑related share withholding. On February 1, 2026, 948 shares of common stock were withheld at $78.97 per share to cover tax obligations from vesting restricted stock units. After this transaction, Saccaro beneficially owned 57,646 shares of GE HealthCare Technologies common stock, held directly.
GE HealthCare Technologies Inc. President and CEO Peter J. Arduini had 3,210 shares of common stock withheld on February 1, 2026 to cover taxes on vesting restricted stock units. The shares were valued at $78.97 each for this tax withholding event.
After this transaction, Arduini directly beneficially owned 164,672 shares of GE HealthCare Technologies Inc. common stock. This was a tax-related share withholding by the company rather than an open-market sale.
GE HealthCare Technologies Inc. arranged new debt financing to support its acquisition of Intelerad Medical Systems. The company entered into a three-year senior unsecured term loan credit facility that provides a committed $750 million term loan, to be drawn in a single borrowing on a later date once customary conditions are met and repaid in full on the third anniversary of funding. Interest can be based on either an alternate base rate or term SOFR for selected interest periods, with a margin tied to the company’s senior unsecured long-term debt ratings.
The credit agreement includes customary covenants limiting liens, certain fundamental transactions, leverage levels, and subsidiary indebtedness, along with standard events of default such as missed payments, covenant breaches, cross-acceleration of other material debt, bankruptcy events, material judgments, and change of control. Separately, GE HealthCare issued $600 million of 4.150% senior notes due December 15, 2028 and $650 million of 4.950% senior notes due December 15, 2035 under an effective shelf registration. The company plans to use the net proceeds from these notes, together with the term loan and cash on hand, to pay the purchase price of the Intelerad acquisition.
GE HealthCare Technologies reported third‑quarter results reflecting steady growth. Total revenues were $5,143 million, up from $4,863 million a year ago, driven by higher product sales and services. Net income attributable to GE HealthCare was $446 million versus $470 million, and diluted EPS was $0.98 compared with $1.02. Operating income was $653 million, modestly below $676 million last year, as higher cost of products offset revenue gains.
For the first nine months, revenues reached $14,927 million and diluted EPS was $3.26. Cash from operating activities was $937 million. The company closed the acquisition of the remaining 50% of Nihon Medi‑Physics for $271 million cash consideration and recognized a $97 million remeasurement gain. It also issued $650 million 4.800% notes due 2031 and $850 million 5.500% notes due 2035. Cash and equivalents were $4,027 million, and total principal debt was $10,275 million. RPO was $15,096 million, indicating future revenue under contract. The company repurchased $200 million of stock year‑to‑date and declared dividends of $0.105 per share. Shares outstanding were 455,521,592 as of October 22, 2025.
GE HealthCare Technologies Inc. (GEHC) furnished its third quarter 2025 financial results press release on an 8-K dated October 29, 2025. The press release is included as Exhibit 99.
The Item 2.02 information is furnished, not filed, and is not subject to Section 18 liabilities or incorporated by reference unless expressly stated. GE HealthCare’s common stock trades on Nasdaq under the symbol GEHC.
Form 144 notice for GE HealthCare Technologies Inc. (GEHC) discloses a proposed sale of 19,524 common shares through UBS Financial Services on 09/22/2025 on NASDAQ with an aggregate market value of $1,453,773. The filing lists the outstanding share count as 456,562,037. The shares were acquired through restricted stock vesting in four tranches between 09/01/2024 and 09/01/2025, totaling the listed units. The filer also reported a prior sale by Kenneth Stacherski of 11,757 shares on 09/12/2025 for gross proceeds of $905,590. The notice includes the standard attestation that the seller is not aware of undisclosed material adverse information.